NASDAQ:SGEN Seagen (SGEN) Stock Price, News & Analysis Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$228.74▼$228.7450-Day Range$228.74▼$228.7452-Week Range$123.77▼$228.96Volume86 shsAverage Volume1.48 million shsMarket Capitalization$42.93 billionP/E RatioN/ADividend YieldN/APrice Target$229.00 Stock AnalysisStock Analysis Get Seagen alerts: Email Address Seagen MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside0.1% Upside$229.00 Price TargetShort InterestN/ADividend StrengthN/ASustainability-2.86Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($3.82) to ($1.82) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.26 out of 5 starsMedical Sector881st out of 910 stocksBiotechnology Industry6th out of 8 stocks 1.0 Analyst's Opinion Consensus RatingSeagen has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageSeagen has received no research coverage in the past 90 days.Read more about Seagen's stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for SGEN. Previous Next 0.0 Dividend Strength Dividend YieldSeagen does not currently pay a dividend.Dividend GrowthSeagen does not have a long track record of dividend growth. Previous Next 2.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreSeagen has received a 13.40% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Brentuximab vedotin", "Enfortumab vedotin", and "Tucatinib" products. See details.Environmental SustainabilityThe Environmental Impact score for Seagen is -2.86. Previous Next 0.6 News and Social Media Coverage Search Interest1 people have searched for SGEN on MarketBeat in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Seagen insiders have not sold or bought any company stock.Percentage Held by Insiders25.90% of the stock of Seagen is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions84.26% of the stock of Seagen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Seagen's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Seagen are expected to grow in the coming year, from ($3.82) to ($1.82) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Seagen is -57.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Seagen is -57.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSeagen has a P/B Ratio of 15.15. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsWhat is Nvidia’s New $1 Trillion SuperProject?Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …Find out details on these three critical Nvidia partners immediately. About Seagen Stock (NASDAQ:SGEN)Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. It offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of adult patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. The company also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-TGT and SEA-CD70 for various cancer diseases. It has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington. As of December 14, 2023, Seagen Inc. operates as a subsidiary of Pfizer Inc.Read More Ad Weiss RatingsWhat is Nvidia’s New $1 Trillion SuperProject?Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …Find out details on these three critical Nvidia partners immediately. SGEN Stock News HeadlinesMay 27, 2024 | seekingalpha.comPfizer: Turning The Corner (Rating Upgrade)April 13, 2024 | wsj.comTwo Brothers, a Big Biotech Bet and an $8 Billion PayoutSeptember 7, 2024 | Porter & Company (Ad)War on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.March 20, 2024 | msn.comRon Baron Portfolio Magic: Building Your Financial FutureMarch 13, 2024 | msn.comBailouts are back, Fed outlook reassessed, Pfizer M&A - what's moving marketsMarch 1, 2024 | bizjournals.comPfizer shutting down Seagen's $350M construction project in EverettFebruary 24, 2024 | finance.yahoo.comNeuralink’s First Brain Implant Patient Can Control Mouse with Thoughts, Musk SaysFebruary 23, 2024 | finance.yahoo.comMRNA Feb 2024 64.000 putSeptember 7, 2024 | Porter & Company (Ad)War on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.February 23, 2024 | finance.yahoo.comMRNA Feb 2024 77.000 callFebruary 23, 2024 | msn.comPfizer adds bull at Guggenheim on ex-COVID prospectsFebruary 22, 2024 | finance.yahoo.comMRNA Feb 2024 67.000 putFebruary 12, 2024 | msn.comPfizer touts cancer efforts in first Super Bowl commercialFebruary 10, 2024 | finance.yahoo.comPRIMECAP Management's Strategic Exits and New Positions Highlight Q4 MovesJanuary 29, 2024 | msn.comPfizer Q4 results on deck amid gloomy earnings outlookJanuary 28, 2024 | za.investing.comPro Research: Wall Street eyes Seagen's growth trajectoryDecember 30, 2023 | ca.finance.yahoo.comSGEN Jan 2024 210.000 putDecember 30, 2023 | ca.finance.yahoo.comSGEN Jan 2024 235.000 put(CONTRSee More Headlines Receive SGEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Seagen and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/01/2023Today9/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:SGEN CUSIP81257810 CIK1060736 Webwww.seattlegenetics.com Phone(425) 527-4000Fax425-527-4001Employees3,256Year Founded1998Price Target and Rating Average Stock Price Target$229.00 High Stock Price Target$229.00 Low Stock Price Target$229.00 Potential Upside/Downside+0.1%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($4.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-610,310,000.00 Net Margins-32.61% Pretax Margin-32.12% Return on Equity-28.06% Return on Assets-20.92% Debt Debt-to-Equity RatioN/A Current Ratio2.67 Quick Ratio2.12 Sales & Book Value Annual Sales$2.30 billion Price / Sales18.66 Cash FlowN/A Price / Cash FlowN/A Book Value$15.10 per share Price / Book15.15Miscellaneous Outstanding Shares187,698,000Free Float139,084,000Market Cap$42.93 billion OptionableOptionable Beta0.32 Social Links 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. David R. Epstein B.Sc. (Age 61)M.B.A., CEO & Director Comp: $1.39MMr. Todd E. Simpson (Age 62)Chief Financial Officer Comp: $1.26MDr. Vaughn B. Himes Ph.D. (Age 62)Chief Technical Officer Comp: $1.08MMs. Jean I. Liu J.D. (Age 55)M.S., Chief Legal Officer & Corporate Secretary Comp: $1.23MMr. Charles R. Romp (Age 55)Executive Vice President of Commercial U.S. Comp: $1.08MDr. Roger D. Dansey M.D. (Age 67)Chief Medical Officer and President of Research & Development Comp: $2.48MMr. William ComptonSenior VP of Global Information Technology & CIOMr. David CaouetteVice President of Corporate CommunicationsMr. Matt SkeltonVice President of MarketingMs. Peggy M. PinkstonChief Human Resources OfficerMore ExecutivesKey CompetitorsBio-TechneNASDAQ:TECHQiagenNYSE:QGENCRISPR TherapeuticsNASDAQ:CRSPDenali TherapeuticsNASDAQ:DNLISpectrum PharmaceuticalsNASDAQ:SPPIView All CompetitorsInsidersDavid R EpsteinSold 10,620 sharesTotal: $2.26 M ($213.01/share)Vaughn B HimesSold 8,785 sharesTotal: $1.87 M ($213.32/share)Roger D DanseySold 71 sharesTotal: $14,661.50 ($206.50/share)Charles R RompSold 45 sharesTotal: $9,292.50 ($206.50/share)Vaughn B HimesSold 80 sharesTotal: $16,520.00 ($206.50/share) Should I Buy Seagen Stock? SGEN Pros and Cons Explained Pros Here are some ways that investors could benefit from investing in Seagen Inc.: Seagen Inc. has shown a consistent increase in institutional ownership percentage, currently standing at 91.8%. Institutional ownership can indicate confidence in the company's future prospects. The company's stock price has been on an upward trend, with the price on record date being $214.03. This positive price movement can attract investors looking for potential capital gains. Seagen Inc. has a relatively low short percentage of float, indicating lower levels of bearish sentiment among investors. This can contribute to price stability and potential upward momentum. The company has a strong fifty-two week performance of 67.25%, outperforming the market average. This positive performance can be appealing to investors seeking growth opportunities. Seagen Inc. has a healthy average daily volume of 1,360,000 shares traded. Higher trading volumes can signify active investor interest and liquidity in the stock. Cons Investors should be bearish about investing in Seagen Inc. for these reasons: Despite the positive aspects, Seagen Inc. has experienced a slight increase in shares shorted from the previous month, indicating some bearish sentiment in the market. This could potentially lead to increased volatility in the stock price. These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, August 26, 2024. Please send any questions or comments about these Seagen pros and cons to contact@marketbeat.com. SGEN Stock Analysis - Frequently Asked Questions How were Seagen's earnings last quarter? Seagen Inc. (NASDAQ:SGEN) posted its quarterly earnings data on Wednesday, November, 1st. The biotechnology company reported ($1.15) EPS for the quarter, missing the consensus estimate of ($0.82) by $0.33. The company's revenue for the quarter was up 27.1% on a year-over-year basis. What is Clay B. Siegall's approval rating as Seagen's CEO? 107 employees have rated Seagen Chief Executive Officer Clay B. Siegall on Glassdoor.com. Clay B. Siegall has an approval rating of 99% among the company's employees. This puts Clay B. Siegall in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. Does Seagen have any subsidiaries? Seagen subsidiaries include these companies: Cascadian Therapeutics. What other stocks do shareholders of Seagen own? Based on aggregate information from My MarketBeat watchlists, some other companies that Seagen investors own include NVIDIA (NVDA), AbbVie (ABBV), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Salesforce (CRM), QUALCOMM (QCOM) and Tesla (TSLA). This page (NASDAQ:SGEN) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredThe death of Nvidia?Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Seagen Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Seagen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.